Eli Lilly (LLY)

Their prospects look intact despite some recent roadblocks.

The "Magnificent Seven" stocks have done incredibly well over the past five years, with six of them more than doubling in value during that time frame.

The attraction of these dividend stocks isn't limited to their dividends.

The healthcare industry is currently experiencing a transformative "golden age," a period marked by an unprecedented surge in scientific breakthroughs and technological advancements. This era is fundamentally altering the landscape of medical treatment and diagnostics, promising a future of more personalized, precise, and preventive medicine. At the forefront of this

A U.S. appeals court upheld a $183.7 million judgment against Eli Lilly in a whistleblower case, finding the company misreported drug prices and shorted Medicaid rebates.

We should know a lot more by year-end.

The positives for this big drugmaker appear to outweigh the negatives.

The Vanguard Growth ETF provides concentrated exposure to the market's most innovative giants and has a proven history of strong, long-term returns.

One of them is already a leader in the market for weight management drugs, and the other could join this field.

Lilly could launch its GLP-1 pill by this time next year.

A decade from now, you could regret ignoring these no-brainer stock picks.

These companies each are leaders in today's highest-growth industries.

Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs.

ICER finds semaglutide and tirzepatide cost-effective for obesity but flags major affordability concerns and limited patient access at current prices.

A fund like the Vanguard Dividend Appreciation ETF can help hedge against a potential market pullback.

Novo Nordisk (NYSE: NVO) has announced a significant restructuring plan that will see the company cut 9,000 jobs, representing 11.5% of its workforce. The decision comes as the pharmaceutical giant faces mounting pressure from U.S. competitor Eli Lilly (NYSE: LLY).

Defiance's LLYZ ETF offers 2X inverse daily exposure to Eli Lilly, giving traders a high-risk, short-term way to bet on stock pullbacks without shorting.

Eli Lilly's new TuneLab platform gives biotech firms AI-powered drug discovery tools using $1 billion of proprietary research.

Trump's policies have sparked a $350B investment surge in US biotech, creating job & revenue opportunities. Investors can track with XBI or IBB ETFs and consider JNJ, NVS, LLY, AZN, BMY as potential winners in this booming sector.

The platform will provide biotech companies access to drug discovery models trained on years of Lilly's research data, the company stated.

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who lost money in tech stocks during 2022.